Overview

EGCG for Hepatocellular Carcinoma Chemoprevention

Status:
Not yet recruiting

Trial end date:
2028-08-31

Target enrollment:

Participant gender:

Summary

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Epigallocatechin gallate